| Jun 21 |
Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
| Jun 20 |
Fortress Biotech files to sell 2.35M shares of common stock for holders
|
| Jun 20 |
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
|
| Jun 20 |
Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
| Jun 17 |
Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy
|
| May 17 |
Fortress Biotech files for $50M mixed shelf
|
